Literature DB >> 12682150

Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.

Daniel R Kuritzkes1, Robert M Grant, Paul Feorino, Marshal Griswold, Marie Hoover, Russell Young, Stephen Day, Robert M Lloyd, Caroline Reid, Gillian F Morgan, Dean L Winslow.   

Abstract

The TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System are designed to sequence the protease (PR)- and reverse transcriptase (RT)-coding regions of human immunodeficiency virus type 1 (HIV-1) pol. Studies were undertaken to determine the accuracy of this assay system in detecting resistance-associated mutations and to determine the effects of RNA extraction methods, anticoagulants, specimen handling, and potentially interfering substances. Samples were plasma obtained from HIV-infected subjects or seronegative plasma to which viruses derived from wild-type and mutant infectious molecular clones (IMC) of HIV-1 were added. Extraction methods tested included standard and UltraSensitive AMPLICOR HIV-1 MONITOR, QIAGEN viral RNA extraction mini kit, and QIAGEN Ultra HIV extraction kit, and NASBA manual HIV-1 quantitative NucliSens. Sequence data from test sites were compared to a "gold standard" reference sequence to determine the percent agreement. Comparisons between test and reference sequences at the nucleotide level showed 97.5 to 100% agreement. Similar results were obtained regardless of extraction method, regardless of use of EDTA or acid citrate dextrose as anticoagulant, and despite the presence of triglycerides, bilirubin, hemoglobin, antiretroviral drugs, HIV-2, hepatitis C virus (HCV), HBV, cytomegalovirus, human T-cell leukemia virus type 1 (HTLV-1), or HTLV-2. Samples with HIV-1 RNA titers of >or=1,000 copies/ml gave consistent results. The TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System consistently generate highly accurate sequence data when tested with IMC-derived HIV and patient samples.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682150      PMCID: PMC153857          DOI: 10.1128/JCM.41.4.1594-1599.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.

Authors: 
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

Authors:  Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

3.  Accuracy of the TRUGENE HIV-1 genotyping kit.

Authors:  Robert M Grant; Daniel R Kuritzkes; Victoria A Johnson; John W Mellors; John L Sullivan; Ronald Swanstrom; Richard T D'Aquila; Mark Van Gorder; Mark Holodniy; Robert M Lloyd; Caroline Reid; Gillian F Morgan; Dean L Winslow
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

4.  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.

Authors:  Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo Viciana; Juan González; Pere Domingo; Charles Boucher; C Rey-Joly; Bonaventura Clotet
Journal:  AIDS       Date:  2002-01-25       Impact factor: 4.177

5.  HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

Authors:  A R Zolopa; R W Shafer; A Warford; J G Montoya; P Hsu; D Katzenstein; T C Merigan; B Efron
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

6.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Authors:  S J Little; E S Daar; R T D'Aquila; P H Keiser; E Connick; J M Whitcomb; N S Hellmann; C J Petropoulos; L Sutton; J A Pitt; E S Rosenberg; R A Koup; B D Walker; D D Richman
Journal:  JAMA       Date:  1999 Sep 22-29       Impact factor: 56.272

7.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  J D Baxter; D L Mayers; D N Wentworth; J D Neaton; M L Hoover; M A Winters; S B Mannheimer; M A Thompson; D I Abrams; B J Brizz; J P Ioannidis; T C Merigan
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

8.  A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients.

Authors:  M J Kozal; R W Shafer; M A Winters; D A Katzenstein; T C Merigan
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

9.  Inhibition of human immunodeficiency virus gene amplification by heparin.

Authors:  M Holodniy; S Kim; D Katzenstein; M Konrad; E Groves; T C Merigan
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

10.  The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.

Authors:  V DeGruttola; L Dix; R D'Aquila; D Holder; A Phillips; M Ait-Khaled; J Baxter; P Clevenbergh; S Hammer; R Harrigan; D Katzenstein; R Lanier; M Miller; M Para; S Yerly; A Zolopa; J Murray; A Patick; V Miller; S Castillo; L Pedneault; J Mellors
Journal:  Antivir Ther       Date:  2000-03
View more
  26 in total

1.  Accuracy of the TRUGENE HIV-1 genotyping kit.

Authors:  Robert M Grant; Daniel R Kuritzkes; Victoria A Johnson; John W Mellors; John L Sullivan; Ronald Swanstrom; Richard T D'Aquila; Mark Van Gorder; Mark Holodniy; Robert M Lloyd; Caroline Reid; Gillian F Morgan; Dean L Winslow
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

2.  Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Authors:  Conan K Woods; Chanson J Brumme; Tommy F Liu; Celia K S Chui; Anna L Chu; Brian Wynhoven; Tom A Hall; Christina Trevino; Robert W Shafer; P Richard Harrigan
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

3.  Genotyping external quality assurance in the World Health Organization HIV drug resistance laboratory network during 2007-2010.

Authors:  Neil Parkin; James Bremer; Silvia Bertagnolio
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

4.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

5.  Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.

Authors:  Michelle Marcial; Jing Lu; Steven G Deeks; Rainer Ziermann; Daniel R Kuritzkes
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

6.  Use of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strains.

Authors:  Diane L Hirigoyen; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

7.  Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.

Authors:  J Michael Kilby; Ha Youn Lee; J Darren Hazelwood; Anju Bansal; R Patterson Bucy; Michael S Saag; George M Shaw; Edward P Acosta; Victoria A Johnson; Alan S Perelson; Paul A Goepfert
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

8.  Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes.

Authors:  Christian B Willberg; Keith E Garrison; R Brad Jones; Duncan A Meiklejohn; Gerald Spotts; Teri J Liegler; Mario A Ostrowski; Annika C Karlsson; Frederick M Hecht; Douglas F Nixon
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

9.  Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene.

Authors:  Jeanne Kowalski; Stephen J Gange; Michael F Schneider; Hua-Ling Tsai; Alan Templeton; Qiujia Shao; Guang Wen Zhang; Mei-Fen Yeh; Mary Young; Richard B Markham
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-01       Impact factor: 3.731

10.  Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing.

Authors:  R M Lloyd; D A Burns; J T Huong; R L Mathis; M A Winters; M Tanner; A De La Rosa; B Yen-Lieberman; W Armstrong; A Taege; D R McClernon; J L Wetshtein; Brian M Friedrich; Monique R Ferguson; William O'Brien; P M Feorino; M Holodniy
Journal:  J Clin Microbiol       Date:  2009-03-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.